The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: -106.00 (-0.87%)
Spread: 2.00 (0.017%)
Open: 12,092.00
High: 12,178.00
Low: 12,010.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-Sterling gains as risk sentiment improves

Tue, 24th Nov 2020 11:39

* Graphic: World FX rates in 2020 http://tmsnrt.rs/2egbfVh

* Graphic: Trade-weighted sterling since Brexit vote http://tmsnrt.rs/2hwV9Hv
(Updates prices and adds latest news)

By Olga Cotaga

LONDON, Nov 24 (Reuters) - Demand for riskier assets on
Tuesday kept sterling close to the two-month high it reached the
day before, with investors also hoping this week's Brexit talks
will result in a deal.

News on Monday that AstraZeneca's potential COVID-19 vaccine
could be up to 90% effective boosted sentiment. British Prime
Minister Boris Johnson said on Monday he hoped almost all
Britons at high risk from COVID-19 would be vaccinated by
Easter.

England will introduce a new system on Dec. 15 allowing
passengers arriving from high-risk countries to take a COVID-19
test after five days of quarantine and to be released from any
further self-isolation if they test negative.

In addition, the one-month full lockdown in England is due
to end on Dec. 2.

Still, Britain is likely to suffer some long-term economic
scarring due to the pandemic, Bank of England policymaker
Jonathan Haskel said.

Sterling was stronger in early trading, but gave back some
gains after data showed British retail sales have fallen by the
most since June during this month's lockdown across the bulk of
the country.

Month-end investment flows have curtailed gains in sterling
and the pound should be trading higher, said Marshall Gittler,
head of investment research at BDSwiss Group.

"I think the pound could continue the gains next month,
depending of course on how the Brexit talks go," he said.

The pound was last up 0.2% at $1.3352, close to
$1.3396, its highest since Sept. 2, reached on Monday. It was
earlier at $1.3380. If it were to rise above $1.3481, the surge
would propel it to nearly a one-year high.

Versus the euro, moves were more contained, with the pound
down 0.1% at 88.98 pence.

London and Brussels this week continue their negotiations
over their future trading relationship, though time is now
running very short as Britain's post-Brexit transition period
ends in fewer than six weeks.

Without an agreement, Britain would revert to trading with
the EU on World Trade Organization rules, an outcome both sides
believe would disrupt their economies.

Most investors believe a deal will be clinched, even if it
is a bare-bones one that leaves some discussions for later.

Traders were buying more put sterling options - as seen in
the one-month risk reversals levels - which usually means more
people are expecting the pound to fall than to rise in the next
few weeks. The levels are not as low as they were in
mid-September, though.

Britain's car industry body warned a failure to clinch a
Brexit deal could cost the sector 55.4 billion pounds ($74
billion) in tariffs by 2025 and undercut its ability to develop
the next generation of zero-emission vehicles.

(Reporting by Olga Cotaga, editing by Larry King and Mark
Potter)

More News
11 Apr 2024 17:13

FTSE 100 edges lower as financials drag

Lok'nStore surges to all-time high after buyout by Shurgard

*

Read more
11 Apr 2024 17:07

Banks weigh down Europe's STOXX 600 after ECB signals rate cuts

Outlook hike sends Ambu shares up

*

Read more
11 Apr 2024 15:56

London close: Stocks finish lower as ECB stands pat

(Sharecast News) - London's stock markets finished in negative territory on Thursday, as investors reacted to the European Central Bank's latest policy announcement and a producer price index release in the United States.

Read more
11 Apr 2024 11:50

LONDON MARKET MIDDAY: Europe takes hit on nerves ahead of ECB decision

(Alliance News) - European equities sunk lower at midday on Thursday, with sentiment hurt by hotter-than-expected inflation from the US crushing hopes of interest rate cuts.

Read more
11 Apr 2024 08:56

TOP NEWS: Astra plans 7% dividend hike for 2024 after no rise in 2023

(Alliance News) - AstraZeneca PLC said it intends to raise its annualised dividend for 2024, citing confidence in its business performance and cash generation.

Read more
11 Apr 2024 08:54

LONDON MARKET OPEN: European markets mixed ahead of ECB decision

(Alliance News) - European equities lacked direction early Thursday morning, ahead of an interest rate decision from the European Central Bank this afternoon.

Read more
11 Apr 2024 07:49

LONDON BRIEFING: Astra promises dividend hike; Darktrace ups guidance

(Alliance News) - Stocks in London are called to open slightly higher on Thursday, as investors eye the latest interest rate decision from the European Central Bank, a day after a hotter-than-expected US inflation reading.

Read more
11 Apr 2024 07:20

AstraZeneca to hike 2024 dividend by 7%

(Sharecast News) - Biopharma giant AstraZeneca has announced that it will increase its annual dividend by 7%, which the board said demonstrates its confidence in the company's performance and cash generation.

Read more
8 Apr 2024 08:36

TOP NEWS: AstraZeneca hails neurological data for Ultomiris, Soliris

(Alliance News) - AstraZeneca PLC on Monday said long-term data in generalised myasthenia gravis will underscore the "vital role" of its Ultomiris and Soliris antibodies in the treatment landscape.

Read more
8 Apr 2024 07:43

LONDON BRIEFING: Astra hails neurology data; CVS flags cyberattack

(Alliance News) - London's FTSE 100 is called to open a touch higher on Monday, ahead of an interest rate decision in the eurozone and a US inflation reading later in the week.

Read more
8 Apr 2024 07:02

AstraZeneca's Enhurtu cancer gets US green light for adult patients

(Sharecast News) - AstraZeneca and Daiichi Sankyo's Enhertu cancer drug has been approved in the US for adult patients with unresectable or metastatic solid tumours who have received prior systemic treatment and have no satisfactory alternative options.

Read more
8 Apr 2024 06:53

TOP NEWS: AstraZeneca's, Daiichi's Enhertu receives US FDA approval

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Saturday announced that the US Food & Drug Administration has approved their cancer drug conjugate for patients with metastatic HER2-positive solid tumours.

Read more
5 Apr 2024 09:42

AstraZeneca makes "breakthrough" in treating small cell lung cancer

(Alliance News) - AstraZeneca PLC on Friday reported positive results relating to its Imfinzi cancer treatment in phase III trials.

Read more
5 Apr 2024 07:50

LONDON BRIEFING: Shell to book USD600 million first-quarter write-off

(Alliance News) - London's FTSE 100 is called to open lower on Friday, with hawkish remarks from Federal Reserve policymakers and fears of ratcheting Middle East tensions giving investors little to cheer about ahead of the latest US jobs data.

Read more
5 Apr 2024 07:23

AstraZeneca announces positive lung cancer treatment trial results

(Sharecast News) - AstraZeneca announced positive high-level results from a phase three trial demonstrating significant advancements in the treatment of limited-stage small cell lung cancer (LS-SCLC) on Friday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.